ArticleMicrobiology spectrum2021
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Open access · goldAbstract read
In one paragraph
Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- The post antibiotic effect of streptogramins on gram-positive bacteria primarily arises from the type a component.Microbial pathogenesis · 2026Article
- Silver Nanoparticles Produced by Rooibos Kombucha Suppress Bacterial Biofilms and Improve Survival inInternational journal of molecular sciences · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Restoration of β-lactam activity by nacubactam combinations against extensively drug-resistant K. pneumoniae harbouring diverse carbapenem resistance gene.World journal of microbiology & biotechnology · 2026Article
- Unveiling the antibacterial effects of endolysin POE and holin Hol8 from Pseudomonas otitidis phage vB_PotS-PotUPM1.World journal of microbiology & biotechnology · 2026Article
- Combination of Ceftazidime-Avibactam and Meropenem for the Treatment of Pneumonia and Bloodstream Infections Caused by Pan-Drug ResistantInfection and drug resistance · 2026Article
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Functional Genomics of Antibiotic Susceptibility in Enterococcus faecalis From Infective Endocarditis.The Journal of infectious diseases · 2025Article
- Green Synthesis of l‑Cysteine-Functionalized rGO-Silver Nanoparticles for Enhanced Photocatalytic and Antibacterial Applications.ACS omega · 2025Article
- Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?The Journal of antimicrobial chemotherapy · 2025Observational
- Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Difficult-to-TreatAntibiotics (Basel, Switzerland) · 2025Review
- Eco-friendly silver nanoparticles from garlic: a novel therapeutic approach for treatingFrontiers in cellular and infection microbiology · 2025Article
- Article
- Synergistic potential of LeuBMC microbiology · 2024Article
- Inhibition of Oral Pathogenic Bacteria, Suppression of Bacterial Adhesion and Invasion on Human Squamous Carcinoma Cell Line (HSC-4 Cells), and Antioxidant Activity of Plant Extracts from Acanthaceae Family.Plants (Basel, Switzerland) · 2024Article
- In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
María M MonteroInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.ORCID 0000-0001-5991-6804
Sandra Domene OchoaInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.
Carla López-CausapéServicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.
Sonia LuquePharmacy Service, Hospital del Mar, Barcelona, Spain.ORCID 0000-0002-3215-320X
Luisa SorlíInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.
Núria CampilloPharmacy Service, Hospital del Mar, Barcelona, Spain.
Inmaculada López MontesinosInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.
Eduardo PadillaLaboratori de Referència de Catalunya, Barcelona, Spain.
Núria PrimLaboratori de Referència de Catalunya, Barcelona, Spain.
Ariadna Angulo-BrunetPsychology and Education Science Studies, Universitat Oberta de Catalunya, Barcelona, Spain.
Santiago GrauPharmacy Service, Hospital del Mar, Barcelona, Spain.
Antonio OliverServicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.ORCID 0000-0001-8571-2733
Juan P HorcajadaInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Barcelona, Spain.ORCID 0000-0001-9873-5459
Universitat Autònoma de Barcelona · ESHospital Del Mar · ESHealth Research Institute of the Balearic Islands · ESUniversitat Oberta de Catalunya · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug CombinationsDrug Resistance, Multiple, BacterialHumansKineticsMicrobial Sensitivity TestsPseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinationsamikacinaztreonamceftazidime-avibactamcolistincombination therapyPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.